JP2024508746A5 - - Google Patents

Info

Publication number
JP2024508746A5
JP2024508746A5 JP2023549549A JP2023549549A JP2024508746A5 JP 2024508746 A5 JP2024508746 A5 JP 2024508746A5 JP 2023549549 A JP2023549549 A JP 2023549549A JP 2023549549 A JP2023549549 A JP 2023549549A JP 2024508746 A5 JP2024508746 A5 JP 2024508746A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antigen
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508746A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016776 external-priority patent/WO2022178114A1/en
Publication of JP2024508746A publication Critical patent/JP2024508746A/ja
Publication of JP2024508746A5 publication Critical patent/JP2024508746A5/ja
Pending legal-status Critical Current

Links

JP2023549549A 2021-02-17 2022-02-17 4-1bbおよびox40結合タンパク質を含む組成物および使用方法 Pending JP2024508746A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150475P 2021-02-17 2021-02-17
US63/150,475 2021-02-17
PCT/US2022/016776 WO2022178114A1 (en) 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2024508746A JP2024508746A (ja) 2024-02-28
JP2024508746A5 true JP2024508746A5 (cg-RX-API-DMAC10.html) 2025-02-21

Family

ID=80738990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549549A Pending JP2024508746A (ja) 2021-02-17 2022-02-17 4-1bbおよびox40結合タンパク質を含む組成物および使用方法

Country Status (8)

Country Link
US (1) US20240150483A1 (cg-RX-API-DMAC10.html)
EP (1) EP4294843A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024508746A (cg-RX-API-DMAC10.html)
KR (1) KR20230167025A (cg-RX-API-DMAC10.html)
CN (1) CN117203236A (cg-RX-API-DMAC10.html)
AU (1) AU2022223692A1 (cg-RX-API-DMAC10.html)
CA (1) CA3208339A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022178114A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
NZ757965A (en) * 2017-03-16 2022-07-01 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody
AU2019301206B2 (en) * 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
JP7539897B2 (ja) * 2019-01-16 2024-08-26 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトcd137に結合する抗体の製剤およびその使用
MX2022001882A (es) * 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.

Similar Documents

Publication Publication Date Title
AU2021245178B2 (en) Stabilized antibody-containing liquid formulations
TWI860988B (zh) 低ph藥物製劑
JP6469765B2 (ja) アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CN106075434B (zh) 含高浓度抗体的溶液制剂
EP3195880B1 (en) High concentration anti-sclerostin antibody formulations
JP2020518600A5 (cg-RX-API-DMAC10.html)
EP3681483B1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
JP2024508762A5 (cg-RX-API-DMAC10.html)
RU2012131099A (ru) Препарат антитела
JP2020509031A5 (cg-RX-API-DMAC10.html)
CN112741804A (zh) 含有抗pd-l1抗体的稳定制剂
JP2024540377A5 (cg-RX-API-DMAC10.html)
JP2026016480A5 (cg-RX-API-DMAC10.html)
JP2023528068A (ja) レビリマブの水性医薬組成物
RU2025101286A (ru) ФАРАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ РЕЦЕПТОРА ПРОГРАМИРУЕМОЙ СМЕРТИ 1 (PD-1) И rHuPH20 ИЛИ ИХ ВАРИАНТОВ ИЛИ ФРАГМЕНТОВ
JP2024543931A5 (cg-RX-API-DMAC10.html)
JP2023501155A (ja) クリザンリズマブ含有抗体製剤
HK40047490A (en) Stable preparation containing anti-pd-l1 antibody
EA043419B1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
HK40033832B (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
HK40033832A (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein